P167 | OUTCOMES OF SECOND-LINE THERAPY IN FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA AFTER DARATUMUMAB-BASED INDUCTION: AN ITALIAN REAL-WORLD STUDY

Introduction Functional high risk multiple myeloma (FHRMM), defined by refractoriness or early relapse after first-line therapy, remains a critical unmet clinical need, associated with limited survival. Although daratumumab-based quadruplet regimens have improved first-line treatment for transplant...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	S. Palmieri, S. Rocco, R. Della Pepa, D. Derudas, D. Roccotelli, D. Esposito, C. Masucci, E. Gigliotta, M.L. Barone, E. Morelli, A. Lazzaro, G. Cetani, F. Accardi, M. Bonanni, A.M. Della Corte, B. Serio, E. Urciuoli, R. Bianco, M. Rizzo, R. Fontana, M. Arcamone, R. Iula, A. Dandolo, A. Leone, M.G. Rascato, M. Di Perna, A.P. Falcone, L. Morello, G. Marcacci, G.R. Nunziata, F. Frigeri, C. Califano, A.M. Carella, A.M. Risitano, M. Annunziata, F. Pane, C. Botta
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12364